Half-year results: Agenix, Progen, C3, Cygenics
24 February, 2005 by Renate KrelleBrisbane's Agenix is not yet out of the red, announcing a net operating loss of AUD$5.2million, up from $2.1 million in the corresponding period last year.
Perlegen promotes improved HapMap
21 February, 2005 by Kevin DaviesWith considerable help from Affymetrix offshoot Perlegen Sciences, the International HapMap Consortium has announced it will build a more detailed map of human genomic variation than originally anticipated.
Alchemia waiting for grant revenue
18 February, 2005 by Renate KrelleJust over half a million in undelivered grant funding has left a hole in Alchemia's (ASX:ACL) accounts, with the company announcing a net loss after tax for the half-year of AUD$4.6 million, compared to $2.7 million in the previous corresponding period.
USCOM gets FDA green light
16 February, 2005 by Renate KrelleSydney heart monitor firm USCOM (ASX:UCM) has received regulatory approval from the US Food and Drug Administration, allowing it to market its devices in the states.
Financial results: Meditech and Optiscan
11 February, 2005 by Melissa TrudingerMeditech Research (ASX: MTR) has reported that its revenues increased 90 per cent to AUD$679,495 while its net loss decreased marginally to $2.7 million during its financial year ending December 31, 2004.
Experimental use of patents may be re-invented
10 February, 2005 by Renate KrelleOne of the legal myths of scientific research -- that using a patented invention is OK as long as that use is only experimental not commercial -- might just become reality later this year.
Becalmed Pfizer reviewing company operations, plans job cuts
10 February, 2005 by Staff WritersPfizer, faced with slowing earnings growth, and safety concerns that have hurt demand for its arthritis products, is conducting a comprehensive review of its operations and is considering job cuts.
Biotechs will bail without bucks, warns Henney
04 February, 2005 by Melissa TrudingerThere is no reason why an Australian biotech company couldn't be the next Amgen, says Chris Henney, the US scientist turned serial entrepreneur who has a seat on Adelaide company Bionomics' board of directors. But he warns that will likely have to move to the US in order to pursue their goal, in part due to the lack of capital available for company growth in Australia.
Chemeq finalises Japanese deal
01 February, 2005 by Melissa TrudingerChemeq's bail-out deal with Japanese investment group Mizuho International has been signed off, and subject to approval from Chemeq's shareholders, the company will receive an injection of cash of at least AUD$40 million.
Optiscan receives $5m order from Pentax
31 January, 2005 by Melissa TrudingerOptiscan (ASX: OIL) has received an order in excess of AUD$5 million from collaborator Pentax to supply miniaturised microscope components for a flexible endo-microscope, as the Japanese company gears up to launch the new product on the market in May.
Govt to measure biotech's economic impact
28 January, 2005 by Renate KrelleThe federal government is about to embark on a project to quantify the great unknown: measuring the economic impact of biotechnology on the Australian economy overall.
Over 3000 keen to use synchrotron
28 January, 2005 by Melissa TrudingerAt least 3000 scientists from Australia, New Zealand and South Africa will be lining up to use the Australian Synchrotron when it opens for business in 2007, according to a report released this week by the project.
Australian scientists honoured
27 January, 2005 by Graeme O'NeillEminent physiologist and founding director of Melbourne's Florey Institute, Professor Derek Denton, was made a Companion (AC) in the General Division of the Australia Day Awards for his service to medical science and Professor Denton made pioneering discoveries about how the brain regulates the body's sodium balance, and fluid and electrolyte levels.
ANSTO to launch STAR accelerator
21 January, 2005 by Susan WilliamsonIn the lead up to the completion of the replacement nuclear reactor at Lucas Heights, the Australian Nuclear Science Technology Organisation (ANSTO) plans to announce a name for the new reactor next week, as well as launch a new Small Tandem for Applied Research (STAR) accelerator.
Starpharma deal with Dow out of the bag
20 January, 2005 by Renate KrelleStarpharma (ASX:SPL) was forced into a trading halt this morning after a report in Melbourne broadsheet The Age revealed that Starpharma's US subsidiary Dendritic Nanotechnologies (DNT) was about to consummate an intellectual property deal with US giant Dow Chemical company.
